WAYNE, Pa.--(BUSINESS WIRE)--Encorium Group, Inc. (Nasdaq: ENCO), a full-service multinational contract research organization (CRO) that provides design, development, and management capabilities for clinical trials and patient registries to many of the world's leading pharmaceutical and biotechnology companies, today announced the resignation of Lawrence R. Hoffman, the Company’s Chief Financial Officer, effective May 2, 2008. Mr. Hoffman has decided to leave the Company to pursue other interests.
